Novel inhibitor of CD4-gp120 binding, blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor

Novel selective inhibitor of nuclear translocation of IKKα as the most potent synthetic gibberellin against cancer-derived cell lines, displaying no cytotoxicity in cells derived from noncancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC)

Non-toxic anti-relapse agent, acamprosate

Non-toxic radioprotector GS-nitroxide, improving hematopoiesis in long-term bone marrow cultures (LTBMCs)

Novel SMAC mimetic, sensitizing non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner

Novel cysteine-reactive covalent ligand, selectively targeting C377 of PPP2R1A to impair breast cancer signaling, proliferation, and in vivo tumor growth

Selective DGAT2 inhibitor

Selective DGAT1 inhibitor

Novel TARP γ-8 Selective AMPAR Negative Modulator

Negative control for JNJ-54119936

Novel inhibitor of respiratory syncytial virus (RSV), binding the RSV F glycoprotein and inhibiting membrane fusion

Novel ago-PAM for the metabotropic glutamate receptor subtype 2 (mGluR2)

Novel inhibitor of PDE10A

Novel potent, orally active LTA4H inhibitor

Negaive control for JNJ-42396302

Negative control for JNJ-40068782

Novel Adenosine A 2A /A 1 Antagonist With Efficacy In Preclinical Models of Parkinson's Disease

Novel potent, selective, and systemically active positive allosteric modulator (PAM) of mGlu2-receptors

Histamine H3 receptor antagonist and serotonin reuptake inhibitor

Selective androgen receptor modulator with minimal prostate hypertrophic activity stimulating sexual behavior in female rats

Novel EthR inhibitor, boosting antituberculous activity of ethionamide

Selective delta opioid receptor agonist as a potent and efficacious antihyperalgesic agent

Novel Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor

Estrogen receptor ESR1 agonist

Vascular endothelial growth factor receptor-2 (VEGF-2) kinase inhibitor

Novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase

Novel potent and selective IRAK1 degrader, effectively degraded cellular IRAK1 protein with a DC50 of 3 nM in HBL-1 cells

Novel Potent Human Adenovirus Inhibitor, showing improved anti-HAdV activity (IC50 = 0.27 μM), significantly decreasing cytotoxicity (CC50 = 156.8 μM), and lowering in vivo toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosam

Novel Potent NS4B Inhibitor for the Treatment of Dengue Virus Infection

Novel inhibitor of viral protease function, suppressing Zika virus Infection both In vitro and In vivo